Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

Company Overview - Axogen, Inc. (NASDAQ: AXGN) is a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function [1][3] - The company focuses specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair [3] Product Portfolio - Axogen offers a comprehensive portfolio of products for peripheral nerve repair, including: - Avance Nerve Graft®, a biologically active processed human nerve allograft for bridging severed peripheral nerves [3] - Axoguard Nerve Connector®, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves [3] - Axoguard Nerve Protector®, a product used to wrap and protect damaged peripheral nerves [3] - Axoguard HA+ Nerve Protector™, designed to enhance nerve gliding and provide protection for peripheral nerve injuries [3] - Avive+ Soft Tissue Matrix™, a multi-layer amniotic membrane allograft for tissue repair [3] - Axoguard Nerve Cap®, used to protect a peripheral nerve end and reduce the development of symptomatic or painful neuroma [3] Market Applications - Axogen's products are utilized across various applications and surgical specialties, including: - Traumatic injuries, oral and maxillofacial surgery, breast reconstruction, and surgical treatment of pain [3] - The company addresses both scheduled procedures, such as nerve reconstruction after surgical removal of painful neuromas, and emergent procedures arising from injuries [3] Upcoming Financial Reporting - Axogen will report its 2025 second quarter financial results on August 5, 2025, before the market opens [1] - An investment-community conference call and webcast will follow the release at 8 a.m. ET [1]